Diabetic foot ulcers: pathogenesis and management
Amid this surge, Novo Nordisk, the company behind GLP-1 drugs Ozempic and Wegovy, has experienced a remarkable rise in its stock price, from roughly $50 per share in 2022 to upwards of $142 in June 2024
GLP-1 receptor agonists work through several pathways: Enhancing insulin secretion from pancreatic beta cells in a glucose-dependent manner, which helps lower blood sugar levels Suppressing glucagon release , thereby reducing hepatic glucose production Slowing gastric emptying , which prolongs satiety and reduces appetite Acting on appetite centres in the brain , particularly the hypothalamus, to decrease food intake While these medications are licensed by the MHRA for type 2 diabetes and, in some formulations (e.g., Saxenda, Wegovy), for chronic weight management, NHS access via NICE guidance is more restricted
What can I expect if I contact a law firm about a potential vision loss case
Hodgkins CC, Cahill KS, Seraphine AE, Frost-Pineda K, Gold MS
